The ASX 200 index is home to a good number of blue chip shares. But which of these shares would make good additions to a portfolio this week?
Three blue chip shares that are highly rated are listed below. Here's what experts are saying about them:
CSL Limited (ASX: CSL)
The first blue chip share to look at is CSL. It is a leading biotherapeutics company which owns the CSL Behring and Seqirus businesses. Combined, these two businesses have a portfolio of life-saving and lucrative therapies and vaccines which are generating billions of dollars in sales each year. But management isn't resting on its laurels. Each year the company invests in the region of 10% to 11% of its sales back into research and development activities every year. This means it is on course to invest ~US$1 billion into these activities this year. This ensures that CSL has a pipeline of potentially lucrative products to support its long term growth.
Analysts at Citi are big fans of the company. The broker currently has a buy rating and $330.00 price target on its shares.
REA Group Limited (ASX: REA)
Another ASX 200 blue share to look at is REA Group. It is the dominant player in real estate listings in the Australian market. In fact, in the first half of FY 2022, during one month the company saw 13.2 million people visit its local site. This is the equivalent of 65% of Australia's adult population. Furthermore, on average, there were 3.3x more visits than the nearest competitor each month. Thanks to this leadership position, new revenue streams, acquisitions, price increases, and its international operations, the company has been tipped to continue its solid growth in the coming years.
Goldman Sachs remains very positive on REA Group. Its analysts currently have a buy rating and $164.00 price target on its shares.
ResMed Inc. (ASX: RMD)
A final blue chip ASX 200 share to look at is ResMed. It is a medical device company with a focus on the growing sleep treatment market. Thanks to its industry-leading products, wide distribution network, and successful acquisitions, ResMed has been growing at a very strong rate over the last few years. Pleasingly, thanks to its significant market opportunity and the growing prevalence of sleep disorders, analysts are tipping the company to continue its growth for the foreseeable future.
Morgans is bullish and has an add rating and $37.95 price target on its shares.
